Products
Dibotatug Biosimilar Monoclonal Antibody (CD94) for Research
Cat No.: GMP-Bios-INN-1161
Anti-KLRD1/CD94 therapeutic antibody (Pre-made Dibotatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Dibotatug (development code DR-01) is a monoclonal antibody targeting CD94/NKG2 family receptor (KLRD1). It is developed by Dren Bio for large granular lymphocytic leukaemia/lymphoma, autoimmune disorders. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1161-1mg | 1mg | 3090 |
| GMP-Bios-INN-1161-10mg | 10mg | |
| GMP-Bios-INN-1161-100mg | 100mg | |
| GMP-Bios-INN-1161-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Dibotatug biosimilar, Whole mAb, Anti-KLRD1/CD94 Antibody: Anti-CD94/KLRD1/Natural killer cells antigen CD94/KP43 therapeutic antibody |
| INN Name | Dibotatug |
| Target | KLRD1/CD94 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Dren Bio |
| Conditions Approved | na |
| Conditions Active | Large granular lymphocytic leukaemia Lymphoma;Autoimmune disorders |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | Transgenic Mouse |
